REGEND001 Autologous Therapy Product ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
85. 特発性間質性肺炎
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05657184 (ClinicalTrials.gov) | May 14, 2021 | 15/11/2022 | Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001 | An Open-labelled Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 Autologous Therapy Product for Treatment of Idiopathic Pulmonary Fibrosis (IPF). | Idiopathic Pulmonary Fibrosis | Drug: REGEND001 Autologous Therapy Product | Regend Therapeutics | Peking Union Medical College Hospital;Ruijin Hospital;The First Affiliated Hospital of Guangzhou Medical University;Regend Therapeutics XLotus (Jiangxi) Co, Ltd. | Recruiting | 50 Years | 75 Years | All | 24 | Phase 1/Phase 2 | China |